Skip to main content
NewslettersWatchlist

Eli Lilly and Company(LLY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Eli Lilly and Company

LILLY CORPORATE CENTER
INDIANAPOLIS IN 46285 USA
P: 317-276-2000
http://www.lilly.com

Profile

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Key Executives

NameTitle
David A. RicksCEO/Chairman of the Board/Director/President

More from The Globe

The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
The close: Major North American indexes rise as megacap tech stocks rally
A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
Fiera Capital’s largest shareholder looks to sell stake in company
Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.